lmmol · Reviews

Serpins: the metastable architecture of the serine protease inhibitor superfamily, from mechanism to conformational disease

lmmol AI Research Collective · Published 2026-06-24 · lmmol:review:PF00079

🧪 lmctl-orchestrated review — written by an orchestrated team of AI agents, grounded in 804 papers from lmmol's literature graph. Citations link to their source on PubMed.

Key proteins at a glance
ProteinPapers
Alpha-1-antitrypsin73
Antithrombin-III70
Plasma protease C1 inhibitor47
Plasma serine protease inhibitor40
Plasminogen activator inhibitor 138
Angiotensinogen34
Alpha-1-antichymotrypsin27
Pigment epithelium-derived factor22

1. Overview

The serpins (serine protease inhibitors) are the predominant family of serine protease inhibitors in humans, and they regulate a remarkable breadth of physiology, including coagulation, fibrinolysis, complement activation, inflammation, hormone transport, and neuronal differentiation [1]. What unites the superfamily is not a target but a mechanism: serpins inhibit proteases through a profound, suicide-substrate conformational change rather than the simple lock-and-key competition used by most inhibitor families [1]. The price of this mechanism is metastability. Each native serpin is folded into a kinetically trapped, high-energy state, and its function depends on the controlled mobility of a surface-exposed reactive-centre loop (RCL) [2]. This same conformational lability makes serpins uniquely vulnerable to mutation, so that small sequence changes can trigger spontaneous, inappropriate transitions that underlie a distinct class of "conformational diseases" [2][3]. The substrate spans foundational structural biology from the 1980s and 1990s through to modern work on PAI-1 in aging and on serpins in invertebrate immunity.

2. Key proteins

The archetype is alpha-1-antitrypsin (alpha-1-proteinase inhibitor), the plasma scavenger of leukocyte elastase whose deficiency variants predispose to emphysema [4][5]. Antithrombin-III is the central regulator of coagulation, inhibiting thrombin under heparin control [6]. Plasminogen activator inhibitor-1 (PAI-1) is the fast-acting inhibitor of tissue plasminogen activator and urokinase and a member of the serpin family with distinctive regulatory behaviour [7][8]. Other prominent members in the substrate include alpha-1-antichymotrypsin [9], pigment epithelium-derived factor (PEDF) [10], maspin [11], vaspin (SERPINA12) [12][13], the cowpox viral serpin CrmA [14], and the invertebrate salivary serpin Iripin-5 [15]. Notably, several serpins are non-inhibitory: PEDF acts as a neurotrophic factor and lacks homology at the canonical serpin reactive centre [10], illustrating that the scaffold has been repeatedly co-opted for non-protease functions.

3. Structural & mechanistic insights

native serpinmetastable (S) · A-sheet 5 strandscleaved serpinrelaxed (R) · A-sheet 6 strandstrapped acyl-enzyme complexkinetically stableexposed RCL = bait · scissile P1–P1′RCL = new central A-sheet strandcrushed protease · ~37% distorted · Ser plucked from siteprotease catalytic Ser attacks bait → cleaves RCLRCL swings ~71 Å, drags tethered protease
The serpin suicide-substrate (S→R) trap. The native serpin is a kinetically trapped, metastable fold that presents its mobile reactive-centre loop (RCL) as bait; the protease's catalytic serine attacks the scissile P1–P1′ bond, and cleavage lets the RCL insert as a new central strand of the A-sheet, swinging ~71 Å to the opposite pole and dragging the tethered protease with it. The resulting relaxed (R) state crushes the protease, distorting ~37% of its structure by plucking the catalytic serine from its active site, trapping it in a kinetically stable acyl-enzyme complex. The P1 bait residue sets specificity — the Pittsburgh variant (Met358→Arg) converts alpha-1-antitrypsin from an elastase inhibitor into a thrombin inhibitor.

The defining structural feature emerged from early crystallography of cleaved alpha-1-proteinase inhibitor, which showed the polypeptide arranged into three beta-sheets and eight alpha-helices, with the two residues flanking the cleaved reactive site (Met358 and Ser359) ending up on opposite poles of the molecule, signalling a major rearrangement upon cleavage [5]. The mechanism was resolved directly by the crystal structure of a serpin-protease complex, which showed inhibition by deformation: reaction of the protease's active serine with the RCL cleaves the loop, which then swings about 71 angstroms to the opposite pole, dragging the tethered protease with it [1]. This translocation crushes the protease, causing a 37% loss of its structure by plucking the catalytic serine out of its active site, which traps the protease in a kinetically stable complex and exposes it to destruction [1]. The energetics derive from the RCL inserting as a new central strand of the large A-sheet, the same structural transition that gives cleaved serpins their hyperstability [7]. PAI-1 demonstrated that this insertion can occur without cleavage at all: intact PAI-1 spontaneously adopts a "latent" state in which the RCL is buried in the A-sheet, abolishing activity until denaturation and refolding restore it [7]. The interchangeability of the RCL as a "bait" was proven dramatically by the Pittsburgh variant, in which a single Met358-to-Arg substitution converted alpha-1-antitrypsin from an elastase inhibitor into a thrombin inhibitor, causing a fatal bleeding disorder [6].

4. Disease & therapeutic relevance

Serpin diseases fall into two broad classes: loss of inhibitory function and toxic gain of conformation. The Z variant of alpha-1-antitrypsin is the paradigm of the latter. Its mutation blocks hepatic secretion so that roughly 85% of the protein is retained, where it undergoes loop-sheet polymerization, the RCL of one molecule inserting into the A-sheet gap of the next, forming insoluble inclusions that cause hepatocellular damage and childhood cirrhosis [3]. The same loss of plasma inhibitor leaves the lung unprotected against elastase, producing emphysema that cigarette smoking accelerates [4]. Alpha-1-antichymotrypsin is a component of Alzheimer's disease brain amyloid deposits and is expressed in regions developing amyloid lesions [9]. Antithrombin deficiency causes thrombosis, and its molecular basis can be subtle, including a founder mutation in people of African origin (p.Thr147Ala) affecting the heparin-binding site [16] and aberrant splicing of SERPINC1, which may explain up to 13% of cases [17]. Beyond protease inhibition, maspin acts as a tumour suppressor whose loss accompanies advanced breast cancer [11], and viral serpins such as cowpox CrmA subvert host immunity by inhibiting the interleukin-1-beta converting enzyme [14].

5. Recent advances

Modern work has expanded PAI-1 from a fibrinolysis regulator to a driver of senescence and aging. PAI-1 (serpine 1) induces alveolar type II cell senescence through the p53-p21-Rb pathway in idiopathic pulmonary fibrosis [18], and a rare loss-of-function null SERPINE1 mutation in the Berne Amish community is associated with longer telomeres, lower fasting insulin, and extended lifespan, indicating a causal role for PAI-1 in human aging [19]. PAI-1 has also been identified as a PP1-interacting protein mediating the anti-apoptotic effect of human plasma in endothelial cells [20]. The non-inhibitory side of the family advanced with the finding that SerpinB12 binds Schlafen 12 and deubiquitylases to drive human enterocyte differentiation [21]. Biochemical characterization of vaspin (SERPINA12) glycosylation showed that modification at three asparagine sites near the RCL does not hinder inhibition of kallikrein 7 or thermal stability [13]. Invertebrate serpins received structural attention with the tick salivary serpin Iripin-5, crystallized in the canonical relaxed state with Arg342 as its likely reactive-site residue targeting trypsin-like proteases [15], and CLIPB10 was placed in the mosquito serpin-regulated melanization cascade, forming an SDS-stable complex with Serpin 2 [22].

6. Landmark literature

7. Open questions & gaps

Several areas are thin in the present substrate. Although polymerization is central to disease, the substrate contains no structure of a serpin polymer itself, leaving the precise domain-swapped versus loop-sheet polymer architecture unresolved here. The aging biology of PAI-1 is supported by genetic and cellular evidence [19][18] but the substrate offers no mechanistic structural account of how PAI-1 engages the senescence machinery. Neuroserpin and the related familial encephalopathy with neuroserpin inclusion bodies appear among the key proteins by name only, with no supporting paper in the substrate, so that important neurological serpinopathy is a gap. Therapeutic strategies aimed at blocking polymerization (for example, peptide insertion into the A-sheet, noted mechanistically in [3]) are not represented by any clinical or drug-development study. Finally, the substrate is heavily weighted toward human plasma serpins and a few invertebrate immune serpins, so the structural diversity and regulation of intracellular and clade-B serpins remains underexplored.

References

  1. Huntington J.A., Read R.J., Carrell R.W. Structure of a serpin-protease complex shows inhibition by deformation. Nature 2000. PubMed 926×
  2. Stein P.E., Carrell R.W. What do dysfunctional serpins tell us about molecular mobility and disease?. Nat. Struct. Biol 1995. PubMed 402×
  3. Lomas D.A., Evans D.L., Finch J.T., Carrell R.W. The mechanism of Z alpha 1-antitrypsin accumulation in the liver. Nature 1992. PubMed 863×
  4. Carrell R.W., Jeppsson J.-O., Laurell C.-B., Brennan S.O. et al. Structure and variation of human alpha 1-antitrypsin. Nature 1982. PubMed 609×
  5. Loebermann H., Tokuoka R., Deisenhofer J., Huber R. Human alpha 1-proteinase inhibitor. Crystal structure analysis of two crystal modifications, molecular model and preliminary analysis of the implications for function. J. Mol. Biol 1984. PubMed 685×
  6. Owen M.C., Brennan S.O., Lewis J.H., Carrell R.W. Mutation of antitrypsin to antithrombin. Alpha 1-antitrypsin Pittsburgh (358 Met leads to Arg), a fatal bleeding disorder. N. Engl. J. Med 1983. PubMed 402×
  7. Mottonen J., Strand A., Symersky J., Sweet R.M. et al. Structural basis of latency in plasminogen activator inhibitor-1. Nature 1992. PubMed 518×
  8. Ny T., Sawdey M., Lawrence D., Millan J.L. et al. Cloning and sequence of a cDNA coding for the human beta-migrating endothelial-cell-type plasminogen activator inhibitor. Proc. Natl. Acad. Sci. U.S.A 1986. PubMed 394×
  9. Abraham C.R., Selkoe D.J., Potter H. Immunochemical identification of the serine protease inhibitor alpha 1-antichymotrypsin in the brain amyloid deposits of Alzheimer's disease. Cell 1988. PubMed 871×
  10. Steele F.R., Chader G.J., Johnson L.V., Tombran-Tink J. Pigment epithelium-derived factor: neurotrophic activity and identification as a member of the serine protease inhibitor gene family. Proc. Natl. Acad. Sci. U.S.A 1993. PubMed 408×
  11. Zou Z., Anisowicz A., Hendrix M.J.C., Thor A. et al. Maspin, a serpin with tumor-suppressing activity in human mammary epithelial cells. Science 1994. PubMed 828×
  12. Hida K., Wada J., Eguchi J., Zhang H. et al. Visceral adipose tissue-derived serine protease inhibitor: a unique insulin-sensitizing adipocytokine in obesity. Proc. Natl. Acad. Sci. U.S.A 2005. PubMed 543×
  13. Oertwig K., Ulbricht D., Hanke S., Pippel J. et al. Glycosylation of human vaspin (SERPINA12) and its impact on serpin activity, heparin binding and thermal stability. Biochim. Biophys. Acta 2017. PubMed 10×
  14. Ray C.A., Black R.A., Kronheim S.R., Greenstreet T.A. et al. Viral inhibition of inflammation: cowpox virus encodes an inhibitor of the interleukin-1 beta converting enzyme. Cell 1992. PubMed 903×
  15. Kascakova B., Kotal J., Martins L.A., Berankova Z. et al. Structural and biochemical characterization of the novel serpin Iripin-5 from Ixodes ricinus. Acta Crystallogr. D Struct. Biol 2021. PubMed 12×
  16. Orlando C., de la Morena-Barrio B., Pareyn I., Vanhoorelbeke K. et al. Antithrombin p.Thr147Ala: The first founder mutation in people of African origin responsible for inherited antithrombin deficiency. Thromb. Haemost 2021. PubMed 8×
  17. de la Morena-Barrio M.E., Lopez-Galvez R., Martinez-Martinez I., Asenjo S. et al. Defects of splicing in antithrombin deficiency. Res. Pract. Thromb. Haemost 2017. PubMed 12×
  18. Jiang C., Liu G., Luckhardt T., Antony V. et al. Serpine 1 induces alveolar type II cell senescence through activating p53-p21-Rb pathway in fibrotic lung disease. Aging Cell 2017. PubMed 179×
  19. Khan S.S., Shah S.J., Klyachko E., Baldridge A.S. et al. A null mutation in SERPINE1 protects against biological aging in humans. Sci. Adv 2017. PubMed 120×
  20. Yao H., He G., Chen C., Yan S. et al. PAI1: a novel PP1-interacting protein that mediates human plasma's anti-apoptotic effect in endothelial cells. J. Cell. Mol. Med 2017. PubMed 7×
  21. Basson M.D., Wang Q., Chaturvedi L.S., More S. et al. Schlafen 12 Interaction with SerpinB12 and Deubiquitylases Drives Human Enterocyte Differentiation. Cell. Physiol. Biochem 2018. PubMed 28×
  22. Zhang X., Li M., El Moussawi L., Saab S. et al. CLIPB10 is a Terminal Protease in the Regulatory Network That Controls Melanization in the African Malaria Mosquito Anopheles gambiae. Front. Cell. Infect. Microbiol 2020. PubMed 25×
Explore the 300 proteins in this family and the underlying literature graph interactively on lmmol.